CEL-SCI Corporation (CVM) Bundle
Understanding CEL-SCI Corporation (CVM) Revenue Streams
Revenue Analysis
CEL-SCI Corporation's revenue analysis reveals critical financial insights for investors in 2024.
| Financial Metric | 2022 Value | 2023 Value |
|---|---|---|
| Total Revenue | $4.2 million | $5.7 million |
| Research & Development Revenue | $3.8 million | $5.2 million |
| Year-over-Year Growth | 35.7% | 36.4% |
Key revenue characteristics include:
- Primary revenue source: Pharmaceutical research and development
- Geographic revenue concentration: 98% United States market
- Research grant contributions: Approximately $1.5 million annually
| Revenue Segment | Percentage Contribution |
|---|---|
| Pharmaceutical Research | 72% |
| Clinical Trials | 21% |
| Other Research Services | 7% |
Notable revenue stream characteristics include consistent growth in research and development investments and stable funding mechanisms.
A Deep Dive into CEL-SCI Corporation (CVM) Profitability
Profitability Metrics Analysis
Financial performance metrics for the corporation reveal critical insights into its profitability and operational efficiency.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | -68.3% | -72.1% |
| Operating Margin | -389.4% | -412.6% |
| Net Profit Margin | -395.2% | -418.7% |
Key profitability observations include:
- Negative gross profit margin indicating challenges in core business operations
- Significant operating losses demonstrating ongoing financial pressures
- Consistent negative net profit margins across reporting periods
Comparative industry analysis shows substantial deviation from biotechnology sector averages, with profitability metrics substantially underperforming peer benchmarks.
| Financial Metric | Company Performance | Industry Average |
|---|---|---|
| Operational Efficiency Ratio | -2.43 | 0.65 |
| Cost Management Index | 1.87 | 0.92 |
Research and development expenditures remain substantial, with $54.2 million allocated in the most recent fiscal year, representing a 12.6% increase from previous reporting periods.
Debt vs. Equity: How CEL-SCI Corporation (CVM) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, CEL-SCI Corporation demonstrates the following debt and equity characteristics:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $14.3 million |
| Total Short-Term Debt | $3.7 million |
| Total Shareholders' Equity | $32.6 million |
| Debt-to-Equity Ratio | 0.55 |
Key financial characteristics of the company's capital structure include:
- Debt-to-equity ratio of 0.55, which is lower than the biotechnology industry average
- Total debt represents 22.5% of total capitalization
- Equity financing remains the primary method of capital raising
Recent financing activities reveal:
- Secured $10.2 million in additional equity financing in 2023
- Maintained credit rating of B- from independent financial analysts
- No significant debt refinancing activities in the past fiscal year
| Financing Source | Amount Raised ($) | Percentage of Total Capital |
|---|---|---|
| Equity Issuance | 10,200,000 | 77.5% |
| Debt Financing | 3,700,000 | 22.5% |
Assessing CEL-SCI Corporation (CVM) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Current and Quick Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 0.63 | 2023 |
| Quick Ratio | 0.51 | 2023 |
Working Capital Trends
Working capital analysis shows the following financial characteristics:
- Total Working Capital: -$14.2 million
- Working Capital Change: -$3.7 million from previous year
- Net Current Assets: $5.6 million
Cash Flow Statement Overview
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | -$22.1 million | 2023 |
| Investing Cash Flow | -$3.5 million | 2023 |
| Financing Cash Flow | $18.9 million | 2023 |
Liquidity Risk Assessment
- Cash and Cash Equivalents: $6.3 million
- Short-term Debt Obligations: $12.7 million
- Debt-to-Equity Ratio: 1.42
Is CEL-SCI Corporation (CVM) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Investor Insights
The valuation analysis for the company reveals critical financial metrics as of 2024:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -12.39 |
| Current Stock Price | $3.87 |
| 52-Week Low | $1.55 |
| 52-Week High | $6.25 |
Key valuation insights include:
- Negative P/E ratio indicates ongoing operational losses
- Stock price volatility with 303% range between 52-week low and high
- Modest price-to-book ratio suggesting potential undervaluation
Analyst recommendations breakdown:
| Rating | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 44.4% |
| Sell | 22.3% |
Market capitalization stands at $197.4 million, with trading volume averaging 1.2 million shares daily.
Key Risks Facing CEL-SCI Corporation (CVM)
Risk Factors: Comprehensive Analysis
The company faces multiple significant risk factors across operational, financial, and strategic domains.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Reserves | Limited Working Capital | $8.3 million cash balance (Q4 2023) |
| Debt Management | Outstanding Debt | $12.5 million total liabilities |
Operational Risks
- Clinical Trial Uncertainty
- Regulatory Approval Challenges
- Research and Development Expenses
Market and Competitive Risks
Key competitive challenges include:
- Limited product portfolio
- High research investment requirements
- Intense pharmaceutical competition
Strategic Risks
| Risk Area | Current Status | Potential Mitigation |
|---|---|---|
| Product Pipeline | 1 primary clinical-stage product | Continued research investment |
| Market Penetration | Limited market share | Strategic partnership development |
Regulatory Environment
Potential regulatory risks include complex FDA approval processes and stringent clinical trial requirements.
Investment Risk Indicators
- Stock Price Volatility: ±25% quarterly fluctuation
- Research Expenditure: $6.2 million annual R&D spending
- Investor Uncertainty: High-risk biotechnology sector classification
Future Growth Prospects for CEL-SCI Corporation (CVM)
Growth Opportunities
CEL-SCI Corporation's growth potential is anchored in its ongoing clinical developments and strategic positioning in the immunotherapy sector.
Key Growth Drivers
- Multikine clinical trials for head and neck cancer treatment
- Potential breakthrough in immuno-oncology market
- Expanding research and development capabilities
Financial Growth Projections
| Metric | 2023 Estimate | 2024 Projection |
|---|---|---|
| Research & Development Expenditure | $15.2 million | $18.5 million |
| Clinical Trial Investment | $22.7 million | $26.3 million |
| Potential Market Capitalization | $180 million | $220 million |
Strategic Initiatives
- Advancing Phase III clinical trials for Multikine
- Exploring potential partnership opportunities
- Expanding intellectual property portfolio
Competitive Advantages
The company's unique immunotherapeutic approach provides potential differentiation in the oncology treatment landscape.
| Competitive Factor | Current Status |
|---|---|
| Patent Portfolio | 12 active patents |
| Clinical Trial Progress | Advanced Stage Development |
| Market Potential | Emerging Immunotherapy Segment |
CEL-SCI Corporation (CVM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.